Navigation Links
New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
Date:11/7/2007

ORLANDO, Fla., Nov. 7 /PRNewswire-FirstCall/ -- A new analysis presented today from METEOR (Measuring Effects on intima media Thickness: an Evaluation Of Rosuvastatin) showed CRESTOR(R) (rosuvastatin calcium) 40 mg slowed the progression of carotid intima-media thickness (CIMT) in four patient populations at varying levels of risk for cardiovascular disease. The sub- study was conducted in subjects defined by the Framingham risk assessment tool as having less than two or two or more risk factors (RF) and either thinner or thicker CIMT (<1.749 mm [median] vs. Greater Than or Equal To 1.749 mm). Results demonstrated that CRESTOR significantly slowed the progression of CIMT in all four subgroups (all p<0.02), compared to placebo treated subjects who all exhibited significantly higher progression rates. These data were presented at the American Heart Association Scientific Sessions in Orlando, Florida.

The new analysis showed that CRESTOR, when compared with placebo, slows progression of carotid atherosclerosis in subjects at relatively low risk for cardiovascular disease (<2RF + Thinner CIMT; 0.0007 mm/yr v. 0.0123 mm/yr with placebo and <2RF + Thicker CIMT; -0.0012 mm/yr v. 0.0116 mm/yr with placebo). Furthermore, those with more RFs and those with greater baseline thickness in the CRESTOR-treated group exhibited a greater trend toward regression or a greater negative slope (2+RF + Thinner CIMT; -0.0013 mm/yr v. 0.0144 mm/yr with placebo and 2+RF + Thicker CIMT; -0.0071 mm/yr v. 0.015 mm/yr with placebo).

"The METEOR trial continues to provide important information regarding the effects of CRESTOR on atherosclerotic progression in subjects with various degrees of risk based on conventional risk factors and carotid artery wall thickness," said John R. Crouse, III, M.D., lead investigator and Professor of Medicine at Wake Forest University School of Medicine, Winston-Salem, NC.

Atherosclerosis is a progressive disease that typically begins in ea
'/>"/>

SOURCE AstraZeneca
Copyright©2007 PR Newswire.
All rights reserved

4

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
3. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
4. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
5. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
6. New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients
7. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
8. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
9. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
10. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
11. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 2Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 2China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 3Sex based prenatal brain differences found 10503 1Sex based prenatal brain differences found 10503 2Bladder Problems May Often Be Related to Mental Health 59989 1Bladder Problems May Often Be Related to Mental Health 59989 2Why antidepressants dont work for so many 59985 1Why antidepressants dont work for so many 59985 2Why antidepressants dont work for so many 59985 3
Other Medicine News:Health News:MedQuist and Clario Form Partnership to Integrate zVision Radiology Practice Management Software with SpeechQ for Radiology 2Health News:MedQuist and Clario Form Partnership to Integrate zVision Radiology Practice Management Software with SpeechQ for Radiology 3Health News:Turn the Corner Honors Andy Abrahams Wilson, Director of Under Our Skin, for His Dedication in the Fight Against Lyme Disease 2Health News:Turn the Corner Honors Andy Abrahams Wilson, Director of Under Our Skin, for His Dedication in the Fight Against Lyme Disease 3Health News:Corgenix Reports Financial Results for First Quarter of Fiscal 2009 2Health News:Corgenix Reports Financial Results for First Quarter of Fiscal 2009 3Health News:Natural Nutrition Canadian Subsidiary Signs $50.5 Million (CDN) Five Year European Distribution Contract 2Health News:KV Pharmaceutical Company Files Form Reporting Delay in Filing Second Quarter Form 10-Q 2Health News:KV Pharmaceutical Company Files Form Reporting Delay in Filing Second Quarter Form 10-Q 3Health News:KV Pharmaceutical Company Files Form Reporting Delay in Filing Second Quarter Form 10-Q 4Health News:Employers Want National Approach to Health Care&#8212;Still Believe Employer-Based System Works Best: New Survey Looks At Attitudes toward Health Care Reform and Major Health Care Issues. 2Health News:Employers Want National Approach to Health Care&#8212;Still Believe Employer-Based System Works Best: New Survey Looks At Attitudes toward Health Care Reform and Major Health Care Issues. 3